Lung and head/neck cancers exhibit mutation-stabilized Nrf2 enhancing ROS tolerance [81], while breast cancer utilizes Ras/MAPK-dependent Nrf2 activation [82]. Here, NFE2L2 is linked to breast carcinoma.